Pharmaxis Ltd - ESG Rating & Company Profile powered by AI
This page displays a zero-cost ESG assessment for Pharmaxis Ltd. Check the end of the page for potential risks for Pharmaxis Ltd based on industry, geography and marketcap. Other companies in the rating industry group for Pharmaxis Ltd are shown below.
Pharmaxis Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Pharmaxis Ltd | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Pharmaxis Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Pharmaxis Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Pharmaxis Ltd report the average age of the workforce?
Sign up for free to unlockDoes Pharmaxis Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Pharmaxis Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Pharmaxis Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Pharmaxis Ltd offer flexible work?
Sign up for free to unlockDoes Pharmaxis Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Pharmaxis Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Pharmaxis Ltd conduct supply chain audits?
Sign up for free to unlockDoes Pharmaxis Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Pharmaxis Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Pharmaxis Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Pharmaxis Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Pharmaxis Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Pharmaxis Ltd disclose water use targets?
Sign up for free to unlockDoes Pharmaxis Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Pharmaxis Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Pharmaxis Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Pharmaxis Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Pharmaxis Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Pharmaxis Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Pharmaxis Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Pharmaxis Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Pharmaxis Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Pharmaxis Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Pharmaxis Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Pharmaxis Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Pharmaxis Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Pharmaxis Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Pharmaxis Ltd disclose its waste policy?
Sign up for free to unlockDoes Pharmaxis Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Pharmaxis Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Pharmaxis Ltd disclose energy use targets?
Sign up for free to unlockDoes Pharmaxis Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Pharmaxis Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Pharmaxis Ltd
These potential risks are based on the size, segment and geographies of the company.
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.